PACB - ARK Genomic ETF: Likely Economic Victim With Low Institutional Interest

• ARKG historically outperformed in its category based on high early valuation in many of its holdings.
• The fund seems to rationalize weighing on its perceived potential for achievement and not on price trajectory or market capitalization.
• The fund continues to batten down on some stocks, regardless of valuation trajectory.
• ARK's emphasis on cutting-edge research will likely not yield massive gains as macroeconomic outlook turns grim.

For further details see: